Company news
Resverlogix Corp. (TSX:RVX) news
Resverlogix Corp. news releases on 6ix. Latest, Sep 10, 2026: Resverlogix Announces Publication of Scientific Journal Articles Relating to Apabetalone's…
Press releases & updates
Resverlogix Announces Publication of Scientific Journal Articles Relating to Apabetalone's Prevention of Heart Failure
September 10, 2026
Resverlogix Announces Voting Results from the 2026 Meeting of Shareholders
June 24, 2026
Resverlogix Closes US$2 Million Shares-for-Interest Private Placement
May 19, 2026
Resverlogix : Financial Statement Q1 2026
May 15, 2026
Resverlogix : MD&A Q1 2026
May 15, 2026
Resverlogix Corp. Announces Filing of Annual Filings and Revocation of MCTO
April 16, 2026
Resverlogix : Financial Statement Q4 2025
April 10, 2026
Resverlogix Corp. Announces Issuance of MCTO by ASC
April 2, 2026
Resverlogix Corp. Provides Bi-Weekly MCTO Status Update
March 31, 2026
Resverlogix Announces Delay in Filing of Annual Financial Statements, AIF, and MD&A
March 16, 2026
Resverlogix Closes $2.8 Million Shares-for-Interest Private Placement
February 17, 2026
Resverlogix Appoints Bradley Glass to Board of Directors
November 18, 2025
Resverlogix : Financial Statement September 30, 2025
November 13, 2025
Resverlogix Announces Voting Results from the 2025 Meeting of Shareholders
June 30, 2025
Resverlogix : MD&A Q1 2025
May 14, 2025
Resverlogix : Financial Statement Q1 2025
May 14, 2025
Numerous Independent Groups Presented Data that Supports Apabetalone's Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024
September 3, 2024
Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
July 31, 2024
Resverlogix Provides Update Regarding Two-Year Extension of Debenture and Elimination of Conversion Privileges
July 16, 2024
Resverlogix Announces Updated Annual and Special Meeting of Shareholders
May 28, 2024
Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges
May 13, 2024
Resverlogix Announces Change to Its Board of Directors
February 20, 2024
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits
January 11, 2024
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
October 4, 2023
Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
August 29, 2023
Resverlogix Announces Warrant Repricing and One-Year Extension
June 29, 2023
Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders
June 20, 2023
Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients
June 12, 2023
Resverlogix Announces One-Year Extension of Debenture
March 20, 2023
Resverlogix Announces New Research Highlighting Apabetalone's Potential Benefits in Cardiovascular Disease, Heart Failure, and COVID-19
March 2, 2023
The Power Play by The Market Herald Releases Interviews With Else Nutrition, Ayurcann Holdings, and Resverlogix
February 22, 2022
InvestmentPitch Media Video Discusses Resverlogix' Enrollment and Dosing of Patients in a Phase 2b Clinical Trial at a Site at the University of Alberta Hospital in Edmonton, to evaluate Apabetalone as a Potential Oral Treatment for COVID-19 - Video Available on Investmentpitch.com
January 19, 2022
Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment
January 18, 2022
Resverlogix: The Future of Drug Development, CEO Clip Video
December 16, 2021
InvestmentPitch Media Video Discusses Resverlogix' Active Discussions with the Kingdom of Morocco's Ministry of Health for the Launch of COVID-19 Clinical Studies Involving Apabetalone - Video Available on Investmentpitch.com
November 2, 2021
InvestmentPitch Media Video Discusses Resverlogix and Report of its Apabetalone Drug Meeting Primary Endpoint in Pulmonary Arterial Hypertension Investigator Led Pilot Study - Video Available on Investmentpitch.com
September 9, 2021
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Acquires Additional Securities of Resverlogix Corp.
May 21, 2021
Toronto Stock Exchange Introduces the TSX30
September 26, 2019
IIROC Trade Resumption - RVX
May 15, 2019
IIROC Trading Halt - RVX
May 15, 2019
Stonegate Capital Partners Initiates Coverage on Resverlogix Corp. (TSX: RVX)
March 19, 2018
IIROC Trade Resumption - Resverlogix Corp.
October 13, 2017
IIROC Trade Halt - Resverlogix Corp.
October 13, 2017
Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
September 13, 2017
Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
September 5, 2017
Successful CANTOS Inflammation Trial Supports Rationale for Resverlogix' Ongoing BETonMACE Trial
August 29, 2017
Resverlogix Announces Extension of Maturity Date of Loan and Expression of Interest Regarding Strategic Transaction
August 28, 2017
Resverlogix Files 2017 Year-End Disclosure Documents and Announces Plans to Host a Symposium at the European Society of Cardiology Congress 2017
July 25, 2017
Resverlogix Receives Approval Pathway from the FDA as to the Inclusion of USA Patients in the Phase 3 BETonMACE Trial
July 25, 2017
CORRECTION FROM SOURCE: IIROC Trade Halt - Resverlogix Corp.
July 25, 2017